ClinicalTrials.gg
CompletedNCT02182102Updated Jul 18, 2014

Dose Escalation of BIBF 1120 Combined With Pemetrexed in Advanced Non Small Cell Lung Cancer

A Phase 1 interventional study of BIBF 1120 and Pemetrexed in Carcinoma, Non-Small-Cell Lung, sponsored by Boehringer Ingelheim. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-07-18.

Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
26
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 19 studies testing nintedanib in Carcinoma, Non-Small-Cell Lung — 1 open to participants now, 2 under way, none of them phase 3. nintedanib · Carcinoma, Non-Small-Cell Lung.

Enrollment
5th of 19
26 · median 16
Started
2005
with 1 other
Phase 1
9 of 19
none open now
Registered
8th of 19
by date
Lead sponsor
10 of 19
Boehringer Ingelheim

Among the 19 studies testing nintedanib in Carcinoma, Non-Small-Cell Lung, this one is the 5th largest by enrollment, is one of 2 that started in 2005, is one of 9 in phase 1, and was the 8th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,837 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

1 of the 19 studies testing nintedanib in Carcinoma, Non-Small-Cell Lung is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About nintedanib

nintedanib: first FDA approval 2014 (OFEV), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies testing nintedanib in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

The primary objective was to determine the safety, tolerability and maximum tolerate dose (MTD) of BIBF 1120 in combination with pemetrexed. Secondary objectives were to characterize the pharmacokinetic profiles of BIBF 1120 and pemetrexed and to obtain preliminary anti-tumour efficacy information.

03

Conditions studied

  • Carcinoma, Non-Small-Cell Lung
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Pathologic confirmation of , unresectable, or locally advanced NSCLC (non-small cell lung cancer)
  • Disease progression during or following one prior platinum-based (including prior or adjuvant therapy) chemotherapy regimen for advanced disease
  • Bi-dimensionally by one or more techniques (CT (computed tomography), MRI (magnetic resonance imaging), X-ray)
  • Age 18 years or older
  • of at least three (3) months
  • (ECOG) performance score 0-2
  • Written that is consistent with ICH-GCP (International Conference on Harmonization - Good Clinical Practice) guidelines

Exclusion criteria

Exclusion Criteria:

  • Participation in another clinical study within the past 28 days prior to the start of therapy or concomitantly with this study
  • Treatment for NSCLC (except radiotherapy for palliative reasons) within the past 28 days prior to Treatment Day 1 of this trial. All toxicities of the previous therapy must have resolved to baseline prior to Treatment Day 1
  • Patient has received more than one prior chemotherapy regimen for advanced disease
  • Radiotherapy to an area of (unless disease progression had been documented following completion of therapy)
  • Patients who are unwilling or unable to take folic acid and vitamin B12 supplementation
  • Radiotherapy within 4 weeks prior to Treatment Day 1
  • Prior treatment with agents that target the vascular endothelial growth factor (VEGF) pathways, including monoclonal antibody therapy (such as bevacizumab) or tyrosine kinase inhibitors
  • Active (stable for \<28 days, symptomatic, or requiring concurrent or antiepileptic therapy). Patients who have received prior whole brain irradiation and whose brain metastases are stable according to the criteria above will not be excluded
  • Centrally located tumors with radiologic evidence (CT or MRI) of local invasion of major blood vessels, with exception of those tumors which have received prior irradiation and are stable
  • Cavitary or necrotic tumors
  • Sanguinous pleural effusion due to disease or pericardial effusion suspicious for disease
  • Other active diagnosed within the past 3 years (other than non-melanomatous skin cancer)
  • Gastrointestinal abnormalities that would interfere with intake or absorption (with exception of patients with gastric esophageal reflux disease controlled with proton pump inhibitors) of the study drug, such as a requirement for intravenous alimentation, prior surgical procedures affecting absorption, treatment for peptic ulcer disease within the last 6 months, active gastrointestinal bleeding unrelated to cancer (as evidenced by either hematemesis, hematochezia, or melena in the past 3 months and without endoscopic documented resolution), or malabsorption syndromes
  • Significant cardiovascular disease (i.e., uncontrolled hypertension, myocardial infarction within 6 months, unstable angina, serious cardiac arrhythmia, >2 (NYHA) Grade 2 congestive heart failure)
  • History of hemorrhagic or thrombotic event (including ) in the past 12 months or hemoptysis in the past 3 months
  • Patients receiving any anti-coagulant therapy (including coumadin, heparin, low molecular weight heparin, and aspirin
  • Patient has received prior therapy with pemetrexed
  • (ANC) ≤1,500/μl, count ≤100,000/μl, or \<9 gm/dL
  • Total >1.5 mg/dL (26 μmole/L, SI-Unit equivalent), alanine amino transferase () and/or aspartate amino transferase (AST) ≥1.5 X (ULN)
  • Inadequate renal function determined by a serum creatinine level >1.5 X ULN
  • Patient is unable or unwilling to interrupt aspirin or other NSAIDS for a 5-day period (8 days period for long lasting agents like piroxicam)
  • Persistent hematuria or proteinuria (more than trace)
  • Women and men who are sexually active and unwilling to use a medically acceptable method of
  • Pregnancy or breast feeding
  • Known or suspected active alcohol or drug abuse
  • Patients unable to comply with the protocol
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
26 participants (actual)

Study arms

  • Experimental
    BIBF 1120 + Pemetrexed

    Drug: BIBF 1120 · Drug: Pemetrexed

Interventions

06

What researchers measure

Primary outcomes

  1. MTD (maximum tolerated dose) of BIBF 1120 in combination with pemetrexed (500 mg/m2).

    Time frame: up to 126 days

  2. Incidence and intensity of Adverse Events according to the Common Terminology Criteria for Adverse Events (Version 3.0) associated with increasing doses of BIBF 1120.

    Time frame: up to 126 days

Secondary outcomes

  1. AUC0-24 (Area under the plasma concentration-time curve over the dosing interval τ (24 h) following the first dose of uniform intervals τ)

    Time frame: before and up to 6 hours after adminstration in cycle 2

  2. AUC0-tz (AUC over the time interval from zero to the time of the last quantifiable drug concentration)

    Time frame: before and up to 6 hours after adminstration in cycle 2

  3. AUC0-∞ (AUC over the time interval from zero extrapolated to infinity)

    Time frame: before and up to 6 hours after adminstration in cycle 2

  4. %AUCtz-∞ (the percentage of AUC0-∞ that is obtained by extrapolation)

    Time frame: before and 1, 2, 3, 4, 6 hours after first adminstration in cycle 2

  5. Cpre,1 (Pre-dose plasma concentration)

    Time frame: before first administration of BIBF 1120 on day 2 of cycle 2

  6. C24,1 (Plasma concentration at 24 h following the first dose)

    Time frame: 24 hours after the first administration of BIBF 1120 in cycle 2

  7. Cmax (Maximum measured plasma concentration following the first dosing intervals τ)

    Time frame: before and up to 6 hours after adminstration in cycle 2

  8. tmax (Time from dosing to the maximum plasma concentration following the first dosing intervals τ)

    Time frame: before and up to 6 hours after adminstration in cycle 2

  9. λz (Terminal rate constant in plasma)

    Time frame: before and 1, 2, 3, 4, 6 hours after first adminstration in cycle 2

  10. t1/2 (Terminal half-life)

    Time frame: before and 1, 2, 3, 4, 6 hours after first adminstration in cycle 2

  11. MRTpo (Mean residence time after oral administration)

    Time frame: before and 1, 2, 3, 4, 6 hours after first adminstration in cycle 2

  12. CL/F of BIBF 1120 (Apparent clearance)

    Time frame: before and 1, 2, 3, 4, 6 hours after first adminstration of BIBF 1120 in cycle 2

  13. Vz/F of BIBF 1120 (Apparent volume of distribution during the terminal phase)

    Time frame: before and 1, 2, 3, 4, 6 hours after first adminstration of BIBF 1120 in cycle 2

  14. % AUCtz-∞ for pemetrexed

    Time frame: before and 0.25, 1, 2, 4, 6 hours after administration in cycle 2

  15. C24,1 C48,1 (Plasma concentration at 24 h and 48 h following the first dose of treatment cycle

    Time frame: 24 and 28 hours after administration in cycle 2

  16. MRTiv for pemetrexed (Mean residence time after i.v. administration)

    Time frame: before and 0.25, 1, 2, 4, 6 hours after administration in cycle 2

  17. CL (Clearance) for pemetrexed

    Time frame: before and 0.25, 1, 2, 4, 6 hours after administration in cycle 2

  18. Vz for pemetrexed (apparent volume of distribution during the terminal phase following an intravascular dose)

    Time frame: before and 0.25, 1, 2, 4, 6 hours after administration in cycle 2

  19. Vss for pemetrexed (Apparent volume of distribution at steady state)

    Time frame: before and 0.25, 1, 2, 4, 6 hours after administration in cycle 2

  20. Objective tumor response according to the response evaluation criteria in solid tumors (RECIST)

    Time frame: up to 56 months

  21. Duration of objective tumor response (time from best response to onset of tumor progression)

    Time frame: up to 56 months

  22. Time to tumor progression (time from start of treatment to time of documented tumor progression)

    Time frame: up to 56 months

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2005 and a primary completion of May 2010. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 2, 2014
First posted
Jul 8, 2014
Start
Sep 2005
Primary completionActual
May 2010
Last update
Jul 18, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 18, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02182102
Responsible party
Sponsor
First posted
Jul 8, 2014
Start date
Sep 2005
Primary completion
May 2010
Last update
Jul 18, 2014
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nintedanib

Start the discussion